Mar-28-18 Initiated
B. Riley FBR, Inc.
Neutral
$1
Jan-05-18 Initiated
Leerink Partners
Outperform
$2
Jun-13-17 Reiterated
Chardan Capital Markets
Buy
$5 → $2.50
Mar-06-17 Reiterated
Wedbush
Outperform
$8 → $6
Jan-30-17 Downgrade
Wells Fargo
Outperform → Market Perform
Jan-30-17 Downgrade
Needham
Buy → Hold
Dec-07-16 Reiterated
Chardan Capital Markets
Buy
$12 → $5
Nov-02-16 Reiterated
Needham
Buy
$10 → $9
Jul-25-16 Reiterated
Chardan Capital Markets
Buy
$14.50 → $12
Jun-28-16 Reiterated
Needham
Buy
$25 → $10
Jun-28-16 Reiterated
FBR Capital
Outperform
$30 → $9
Jun-28-16 Reiterated
Chardan Capital Markets
Buy
$20 → $13.50
Jun-07-16 Reiterated
Chardan Capital Markets
Buy
$15 → $20
Apr-13-16 Initiated
Chardan Capital Markets
Buy
$15
Dec-04-15 Initiated
Wells Fargo
Outperform
Jun-09-15 Initiated
Guggenheim
Buy
Apr-21-15 Resumed
FBR Capital
Outperform
$30
Nov-24-14 Initiated
Deutsche Bank
Buy
$30
Aug-07-14 Reiterated
FBR Capital
Outperform
$14 → $15
Aug-14-13 Reiterated
Needham
Buy
$8 → $12
Apr-15-21 08:07AM
Apr-07-21 08:07AM
Mar-10-21 04:03AM
Mar-09-21 04:07PM
Mar-05-21 04:07PM
Mar-04-21 12:30PM
Feb-10-21 08:07AM
Jan-27-21 08:07AM
Jan-05-21 08:07AM
Dec-09-20 08:54AM
Dec-08-20 08:07AM
Dec-02-20 07:00AM
Dec-01-20 08:35AM
Nov-29-20 02:33PM
Nov-05-20 05:25PM
04:07PM
Nov-03-20 12:31PM
Nov-02-20 08:07AM
Oct-15-20 08:07AM
Oct-13-20 08:07AM
Sep-11-20 08:07AM
Sep-08-20 08:28AM
Sep-03-20 08:07AM
Aug-31-20 08:07AM
Aug-13-20 06:05PM
04:07PM
Aug-06-20 12:30PM
08:07AM
Aug-03-20 08:07AM
Jul-29-20 08:07AM
Jul-22-20 08:07AM
Jun-12-20 08:01AM
May-14-20 04:07PM
May-07-20 12:30PM
Mar-12-20 04:37PM
Mar-09-20 12:30PM
Feb-13-20 04:30PM
Jan-21-20 07:47AM
Dec-22-19 07:44PM
Dec-16-19 08:00AM
Nov-18-19 08:07AM
Nov-15-19 01:37PM
Nov-12-19 05:55PM
04:05PM
Nov-07-19 10:30AM
Oct-16-19 04:15PM
Sep-20-19 01:30PM
Sep-12-19 08:00AM
Sep-03-19 04:10PM
Aug-29-19 04:10PM
Aug-08-19 07:20PM
04:10PM
Aug-06-19 02:50PM
Aug-01-19 10:33AM
Jul-30-19 08:00AM
Jul-29-19 11:33AM
Jul-23-19 06:30PM
Jun-11-19 05:00AM
May-10-19 05:39AM
May-09-19 04:05PM
May-07-19 04:05PM
May-06-19 09:15AM
09:00AM
May-02-19 10:32AM
Apr-08-19 08:00AM
Mar-28-19 09:45AM
Mar-18-19 08:53AM
08:00AM
Mar-15-19 06:00PM
Jan-07-19 08:00AM
Jan-04-19 04:05PM
Dec-20-18 09:56AM
Nov-28-18 07:35AM
Nov-19-18 08:00AM
Nov-08-18 06:40PM
05:38PM
04:05PM
Nov-06-18 07:30AM
Oct-25-18 04:05PM
Oct-23-18 11:30AM
08:35AM
Oct-22-18 04:05PM
Oct-18-18 04:05PM
Oct-17-18 07:45AM
Oct-04-18 08:05AM
Oct-02-18 04:05PM
Sep-27-18 04:05PM
Sep-26-18 04:05PM
Sep-19-18 02:22PM
Aug-23-18 12:50PM
Aug-09-18 06:10PM
05:05PM
04:05PM
Jul-09-18 09:13AM
Jul-05-18 05:00PM
07:35AM
Jul-03-18 12:38PM American City Business Journals
Jun-12-18 07:45AM
May-17-18 07:40AM
May-10-18 11:46PM Thomson Reuters StreetEvents
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase 1 development for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products, which include RGLS5579 glioblastoma multiforme program; and Hepatitis B virus, non-alcoholic steatohepatitis, and cell therapies programs. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Aker Christopher Ray Sr. VP & General Counsel Feb 16 Sale 1.72 828 1,424 42,614 Feb 17 05:23 PM Hagan Joseph P President and CEO Feb 16 Sale 1.72 4,144 7,128 485,756 Feb 17 05:23 PM Sonsini Peter W. 10% Owner Dec 04 Buy 0.62 4,398,602 2,735,930 6,451,056 Dec 07 05:13 PM Walker Paul Edward 10% Owner Dec 04 Buy 0.62 4,398,602 2,735,930 6,451,056 Dec 07 05:14 PM SANDELL SCOTT D 10% Owner Dec 04 Buy 0.62 4,398,602 2,735,930 6,451,056 Dec 07 05:12 PM MAKOWER JOSHUA 10% Owner Dec 04 Buy 0.62 4,398,602 2,735,930 6,451,056 Dec 07 05:12 PM Florence Anthony A. Jr. 10% Owner Dec 04 Buy 0.62 4,398,602 2,735,930 6,451,056 Dec 07 05:10 PM Makhzoumi Mohamad 10% Owner Dec 04 Buy 0.62 4,398,602 2,735,930 6,451,056 Dec 07 05:11 PM Chang Carmen 10% Owner Dec 04 Buy 0.62 4,398,602 2,735,930 6,451,056 Dec 07 05:10 PM Behbahani Ali 10% Owner Dec 04 Buy 0.62 4,398,602 2,735,930 6,451,056 Dec 07 05:09 PM BASKETT FOREST 10% Owner Dec 04 Buy 0.62 4,398,602 2,735,930 6,451,056 Dec 07 05:08 PM Growth Equity Opportunities V, 10% Owner Dec 04 Buy 0.62 4,398,602 2,735,930 6,451,056 Dec 07 05:06 PM Aker Christopher Ray Sr. VP & General Counsel Nov 16 Sale 0.52 876 456 25,762 Nov 18 04:10 PM Hagan Joseph P President and CEO Nov 16 Sale 0.52 6,094 3,176 215,994 Nov 18 04:09 PM Aker Christopher Ray Sr. VP & General Counsel Aug 14 Sale 0.60 872 528 26,638 Aug 17 08:21 PM Hagan Joseph P President and CEO Aug 14 Sale 0.60 4,245 2,568 222,088 Aug 17 08:22 PM Hagan Joseph P President and CEO May 15 Sale 0.63 4,426 2,774 226,333 May 18 04:28 PM Aker Christopher Ray Sr. VP & General Counsel May 15 Sale 0.63 909 570 27,510 May 18 04:27 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite